Cover Image
市場調查報告書

社區型肺炎:開發平台分析

Community Acquired Pneumonia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 257817
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
社區型肺炎:開發平台分析 Community Acquired Pneumonia - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 100 Pages
簡介

本報告提供社區型肺炎的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等,為您概述為以下內容。

目錄

簡介

社區型肺炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Allergan Plc
  • AstraZeneca Plc
  • Biotest AG
  • C10 Pharma AS
  • kyorin製藥
  • Paratek Pharmaceuticals, Inc.
  • TaiGen Biotechnology Co., Ltd.
  • 武田藥品工業

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BT-086
  • C-10
  • ceftaroline fosamil
  • dalbavancin
  • KRPAM-1977X
  • nemonoxacin
  • omadacycline tosylate
  • ticagrelor

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8996IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2017, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 2, 1 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Community Acquired Pneumonia - Overview
  • Community Acquired Pneumonia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Community Acquired Pneumonia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Community Acquired Pneumonia - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals LLC
    • BioAegis Therapeutics Inc
    • Biotest AG
    • InflaRx GmbH
    • ioGenetics Inc
    • Kyorin Pharmaceutical Co Ltd
    • Lascco SA
    • Melinta Therapeutics Inc
    • Merck & Co Inc
    • Nabriva Therapeutics AG
    • Paratek Pharmaceuticals Inc
    • TaiGen Biotechnology Co Ltd
    • Takeda Pharmaceutical Company Ltd
    • Tetraphase Pharmaceuticals Inc
    • TiGenix NV
    • Wockhardt Ltd
  • Community Acquired Pneumonia - Drug Profiles
    • BT-086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAL-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceftaroline fosamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cx-611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBAF-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lascufloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nafithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nemonoxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PneumoMab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosatoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Community Acquired Pneumonia - Dormant Projects
  • Community Acquired Pneumonia - Discontinued Products
  • Community Acquired Pneumonia - Product Development Milestones
    • Featured News & Press Releases
      • Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
      • Jan 18, 2017: Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
      • Dec 29, 2016: Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
      • Dec 20, 2016: Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
      • Dec 13, 2016: Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017
      • Dec 05, 2016: Launch of Phase III clinical trial for the new macrolide antibiotic "T-4288" in Japan
      • Nov 04, 2016: FDA Advisory Committee Votes That Efficacy Results of Cempras Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
      • Nov 01, 2016: Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
      • Oct 31, 2016: Nabriva Presents Research on Lefamulin at IDWeek 2016
      • Oct 20, 2016: Nabriva Announces Presentations at Upcoming IDWeek 2016
      • Aug 30, 2016: Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
      • Aug 25, 2016: Cempras Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
      • Aug 23, 2016: Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
      • Aug 11, 2016: Cempra Appoints Dr. David Zaccardelli to Board of Directors
      • Jul 05, 2016: Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Community Acquired Pneumonia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics Inc, H1 2017
  • Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2017
  • Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H1 2017
  • Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H1 2017
  • Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Community Acquired Pneumonia - Pipeline by Lascco SA, H1 2017
  • Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc, H1 2017
  • Community Acquired Pneumonia - Pipeline by Merck & Co Inc, H1 2017
  • Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H1 2017
  • Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
  • Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
  • Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Community Acquired Pneumonia - Pipeline by TiGenix NV, H1 2017
  • Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H1 2017
  • Community Acquired Pneumonia - Dormant Projects, H1 2017
  • Community Acquired Pneumonia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Community Acquired Pneumonia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top